Quantcast
Last updated on April 16, 2014 at 1:21 EDT

Latest cell therapy Stories

2014-01-14 23:01:25

A new study released in STEM CELLS Translational Medicine indicates that stem cells can be effective in treating a debilitating and sometimes lethal genetic disorder called brittle bone disease. Durham, NC (PRWEB) January 14, 2014 A new study released in STEM CELLS Translational Medicine indicates that stem cells can be effective in treating a debilitating and sometimes lethal genetic disorder called brittle bone disease. Brittle bone disease, or osteogenesis imperfecta (OI), is...

2014-01-14 16:25:47

Americord announces over 2200% revenue growth outpacing rival cord blood banks CBR and ViaCord NEW YORK, Jan. 14, 2014 /PRNewswire/ -- Americord announced today its continued growth, supporting management's belief that it remains the fastest growing cord blood bank in the United States. 2013 proved to be another record year for Americord and the company is now moving more quickly than ever towards its goal of being the leading provider of cord blood and cord tissue banking services...

2014-01-14 08:30:37

ROCKVILLE, Md., Jan. 14, 2014 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced the appointment of Catherine Angell Sohn, Doctor of Pharmacy (Pharm.D.), to its Board of Directors, bringing the total number of board members to six. Dr. Sohn is the former Senior Vice President of Business Development and Strategic Alliance, GSK Consumer Healthcare, at GlaxoSmithKline, where she spearheaded global commercialization for this $8 billion division and led a series of international...

2014-01-13 16:25:56

Updates on NSI-566 ALS Phase II - cSCI Phase I - Stroke Phase I/II, and NSI-189/MDD ROCKVILLE, Md., Jan. 13, 2014 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that President and CEO Richard Garr will present at the sixth annual Biotech Showcase (http://www.ebdgroup.com/bts/index.php) in San Francisco on Tuesday, January 14, 3:30 p.m. PT, in Room Powell (Track D). Garr will present a business overview, including updates on ongoing and planned clinical trials. Garr will...

2014-01-13 12:27:02

ROCKVILLE, Md., Jan. 13, 2014 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that the first patient was treated in the Phase I/II NSI-566 stem cell trial to treat motor deficits from ischemic stroke at BaYi Brain Hospital in Beijing, China. The patient received treatment on December 27, 2013 and has now returned home. The trial is sponsored by Neuralstem's wholly-owned subsidiary, Neuralstem China (Suzhou Sun-Now Biopharmaceutical Co. Ltd.), which was formed to develop...

2014-01-13 08:28:59

Growing Pipeline of Protein Replacement Therapies for Rare Connective Tissue Disorders EXTON, Pa. and GERMANTOWN, Md., Jan. 13, 2014 /PRNewswire/ -- Fibrocell Science, Inc. (NYSE MKT:FCSC), an autologous cell therapy company primarily focused on developing first-in-class treatments for skin diseases and conditions with high unmet medical needs, and Intrexon Corporation (NYSE: XON), a leader in synthetic biology, announced today an expansion of their Exclusive Channel Collaboration...

artificial bone marrow
2014-01-12 04:47:45

Rebekah Eliason for redOrbit.com - Your Universe Online An exciting breakthrough is offering hope for the treatment of blood diseases such as leukemia using artificial bone marrow. Specialized cells, known as hematopoietic stem cells, located within bone marrow, continuously replace and supply new blood cells such as red blood cells and white blood cells. Traditionally a blood disease like leukemia is treated with bone marrow transplants that supply the patient with new hematopoietic...

2014-01-09 08:29:26

MONT-SAINT-GUIBERT, Belgium, January 9, 2014 /PRNewswire/ -- Cardio3 BioSciences (C3BS) (NYSE Euronext Brussels and Paris: CARD), a leader in the discovery and development of regenerative, protective and reconstructive therapies for the treatment of cardiac diseases, announces today that the U.S. Food and Drug Administration (FDA) has authorized the Company's Investigational New Drug (IND) application for clinical testing of the Company's proprietary regenerative medicine...

2014-01-09 08:29:14

ROCKVILLE, Md., Jan. 9, 2014 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced today that on January 8, 2014, it closed on a $20 million investment from leading institutional and accredited investors in a registered direct placement (the "Offering") of 6,872,859 shares of common stock at a price of $2.91 per share. In addition, the Company issued to the investors in the Offering warrants to purchase common stock equal to one-half of the number of shares purchased by the...

2014-01-08 12:29:43

LONDON, Jan. 8, 2014 /PRNewswire/ -- Edison's comprehensive report on Cardio3 BioSciences, Healing failing hearts, analyses its C-Cure heart regenerative product, which uses a mix of powerful cell-signalling molecules to programme autologous stem cells to develop into heart muscle. This makes C-Cure a potentially powerful novel treatment for patients with weakened, scarred hearts, usually due to previous heart attacks. C-Cure showed positive efficacy endpoints in Phase II and median...